22 results
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
Administration (FDA) and International Headache Society
Unlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer … of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth Edition, Cephalalgia, 2019
Pending
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
, February 2018 50 * Diener et al., Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
, February 2018
Diener et al., Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
in efficacy trials by the FDA and/or International Headache Society guidelines* * FDA Guidance, Migraine: Developing Drugs for Acute Treatment, February 2018 … * Diener et al., Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth Edition, Cephalalgia, 2019
Conference Call and Webcast
8-K
EX-99.1
jbf55g c0h
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
EX-99.1
9teioi xs6mjvg2x2h
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm
8-K
EX-99.1
n7nn4s0s
10 May 22
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results
4:02pm
8-K
EX-99.1
qshszor9g95xqj c6w
15 Mar 22
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
4:40pm
8-K
EX-99.1
bth5epuwrvdp9
9 Nov 21
Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:00pm
8-K
EX-99.1
a8bro0ynbdu8at8pvz6i
11 Aug 20
Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
4:10pm
10-K
prod28ei 5yv
10 Mar 20
Annual report
4:20pm
8-K
EX-99.1
rlhy2h0s
10 Mar 20
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results
4:10pm
8-K
EX-99.1
mp9yp3mgu e5yw03rd8
12 Nov 19
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
4:16pm
424B4
7czr la81ej0
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
2vojsfv o4
3 Sep 19
IPO registration (amended)
6:12am
S-1
c74owfbtav1be7wy
16 Aug 19
IPO registration
5:15pm